Skip to main content Accessibility help
×
Home
Hostname: page-component-558cb97cc8-kwsbc Total loading time: 0.214 Render date: 2022-10-07T02:35:49.951Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "useRatesEcommerce": false, "displayNetworkTab": true, "displayNetworkMapGraph": true, "useSa": true } hasContentIssue true

Perceptions and knowledge of antipsychotics among mental health professionals and patients

Published online by Cambridge University Press:  02 January 2018

Lindah Cahling
Affiliation:
PRIMA, Stockholm, Sweden
Anders Berntsson
Affiliation:
PRIMA, Stockholm, Sweden
Gabriella Bröms
Affiliation:
Karolinska Institutet, Stockholm, Sweden
Lars Öhrmalm*
Affiliation:
PRIMA, Stockholm, Sweden Karolinska Institutet, Stockholm, Sweden
Rights & Permissions[Opens in a new window]

Abstract

HTML view is not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Aims and method

To assess the patients' most influential concerns regarding long-acting injectable antipsychotics (LAIs) and mental health professionals' preconceptions about these concerns. For both groups, to assess the level of knowledge about LAIs. This cross-sectional study used semi-structured interviews of patients with schizophrenia or schizoaffective disorder (n = 164), nurses (n = 43) and physicians (n = 20).

Results

The mental health professionals overestimated many of the patients' fears of LAIs, and the expressed fears exceeded the actual experiences of patients already on LAIs. Acceptance to switch to LAIs was associated with shorter time from diagnosis. Nurses and patients disclosed limited knowledge of antipsychotics.

Clinical implications

Physicians and nurses should aim to identify the individual patient's concerns about LAIs in the discussion about choice of antipsychotic treatment early in the course of illness.

Type
Original Papers
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an open-access article published by the Royal College of Psychiatrists and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 2017 The Authors

Footnotes

Declaration of interest

L.Ö. has received speaker honoraria from Otsuka Pharma Scandinavia AB and H. Lundbeck AB, and has accepted travel and hospitality payment from Otsuka Pharma Scandinavia AB.

References

1 Weiden, PJ. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry 2007; 68 (suppl 14): 14–9.Google ScholarPubMed
2 Weiden, PJ, Kozma, C, Grogg, A, Locklear, J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886–91.CrossRefGoogle ScholarPubMed
3 Subotnik, KL, Nuechterlein, KH, Ventura, J, Gitlin, MJ, Marder, S, Mintz, J, et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry 2011; 168: 286–92.CrossRefGoogle ScholarPubMed
4 Heres, S, Lambert, M, Vauth, R. Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry 2014; 29 (suppl 2): 1409–13.CrossRefGoogle ScholarPubMed
5 Marcus, SC, Zummo, J, Pettit, AR, Stoddard, J, Doshi, JA. Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. J Manag Care Spec Pharm 2015; 21: 754–68.Google ScholarPubMed
6 Kirson, NY, Weiden, PJ, Yermakov, S, Huang, W, Samuelson, T, Offord, SJ, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry 2013; 74: 568–75.CrossRefGoogle ScholarPubMed
7 Dencker, SJ. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. J Clin Psychiatry 1984; 45: 22–7.Google ScholarPubMed
8 Gerlach, J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 1995; 9 (suppl 5): 1720.CrossRefGoogle ScholarPubMed
9 Agid, O, Foussias, G, Remington, G. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention. Expert Opin Pharmacother 2010; 11: 2301–17.CrossRefGoogle ScholarPubMed
10 Waddell, L, Taylor, M. Attitudes of patients and mental health staff to antipsychotic long-acting injections: systematic review. Br J Psychiatry 2009; suppl. 52: S4350.CrossRefGoogle ScholarPubMed
11 Patel, MX, De Zoysa, N, Bernadt, M, David, A. Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 2009; 23: 789–96.CrossRefGoogle Scholar
12 Weiden, PJ, Roma, RS, Velligan, Dl, Alphs, L, DiChiara, M, Davidson, B. The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia. J Clin Psychiatry 2015; 76: 684–90.Google ScholarPubMed
13 Beitinger, R, Kissling, W, Hamann, J. Trends and perspectives of shared decision-making in schizophrenia and related disorders. Curr Opin Psychiatry 2014; 27: 222–9.CrossRefGoogle ScholarPubMed
14 Potkin, S, Bera, R, Zubek, D, Lau, G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry 2013; 13: 261.CrossRefGoogle Scholar
15 Das, AK, Malik, A, Haddad, PM. A qualitative study of the attitudes of patients in an early intervention service towards antipsychotic long-acting injections. Ther Adv Psychopharmacol 2014; 4: 179–85.CrossRefGoogle Scholar
16 Patel, MX, Haddad, PM, Chaudhry, IB, McLoughlin, S, Husain, N, David, AS. Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J Psychopharmacol 2010; 24: 1473–82.CrossRefGoogle ScholarPubMed
17 James, BO, Omoaregba, JO, Okonoda, KM, Otefe, EU, Patel, MX. The knowledge and attitudes of psychiatrists towards antipsychotic long-acting injections in Nigeria. Ther Adv Psychopharmacol 2012; 2: 169–77.CrossRefGoogle ScholarPubMed
18 Subotnik, KL, Casaus, LR, Ventura, J, Luo, JS, Helleman, GS, Gretchen-Doorly, D, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry 2015; 72: 822–9.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.
You have Access Open access
15
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Perceptions and knowledge of antipsychotics among mental health professionals and patients
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Perceptions and knowledge of antipsychotics among mental health professionals and patients
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Perceptions and knowledge of antipsychotics among mental health professionals and patients
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *